Clinical Trial

Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)

Withdrawn Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
New protocol developed
Summary
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired pneumonia (CAP) (with or without sepsis/ARDS) recover. The study will give NAI by subcutaneous injection (Days 1 and 10) and one IV dose of iNKT cells (Day 3), then follow participants for 90 days.
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-05-09
critical Reason stopped changed: — → New protocol developed 2026-05-09
notable Enrollment reduced: 20 -> 0 participants 2026-05-09
Trial Details
NCT Number NCT07492888
Lead Sponsor ImmunityBio, Inc.
Conditions Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
Start Date 2026-04-15
Primary Completion 2026-11-15 (estimated)
Study Completion 2027-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-08